Jason Reed, Ph.D., is a sort of research jack-of-all-trades. He has a broad base of knowledge to pull from – an undergraduate and master’s degrees in physics and a Ph.D. in physical chemistry. While in his doctoral program, he focused on genome analysis of single DNA molecules. Since then, he has focused his research on biological systems – applying imaging approaches that look at how cancer cells grow or how they respond to treatment.
Ensysce Biosciences Inc. announced today that the U.S. Patent Office has issued a Notice of Allowance for U.S. Patent Application No. 13/175,314: SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO. The application has claims covering methods of delivering single walled carbon nanotube (SWCNT) complexes with siRNA for therapeutic applications.
Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections, according to new research led by UCL scientists that could be a breakthrough for the millions worldwide suffering from age-related macular degeneration (AMD) and other eye disorders.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.
Nanoparticles designed for drug delivery run the gamut from very artificial components like gold or specially designed RNA to particles that adapt or mimic naturally occurring nanoparticles. A noteworthy example of the latter is adapting biology’s “good cholesterol”, the high-density lipoprotein particle, to deliver anti-inflammatory drugs to prevent recurrent heart attacks and strokes.
“Now is really the perfect time in history for the university here in Tainan to jump into the field of cryo-EM (cryo-electron microscopy),” said Dr. Robert M. Glaeser, Professor Emeritus of Biochemistry, Biophysics and Structural Biology, UC Berkeley, USA, at a symposium held at National Cheng Kung University (NCKU), Tainan, Taiwan, March 4th.
In current research related to improving cancer treatments, one promising area of research is the effort to find ways to selectively pinpoint and target cancer cells while minimizing effects on healthy cells.
One of the most basic tenets of science is observation, an essential tool with the power not only to prevent but also in some cases redefine failure.
Recognizing the potential of microscopic nanotechnology to revolutionize the field of medicine, the University of Virginia has recruited one of the nation’s top experts to serve as co-director of the Institute for Nanoscale and Quantum Scientific and Technological Advanced Research, or nanoSTAR.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.